EKO Duo Device in Patients with Genetic Heart Diseases

Overview

About this study

The purpose of this study is to evaluate diagnostic accuracy of the EKO DUO System in patients with Genetic Heart Diseases and develop novel algorithms to diagnose these conditions. The device will be placed on the chest (similar to a stethoscope exam) and will simultaneously record an ECG and phonocardiogram (PCG) for up to 120 seconds. Additional data obtained will include clinical characteristics, past medical history, recent medications and procedure, laboratory data, and echocardiographic and ECG studies.

Tools like the EKO Duo device can be used to improve diagnosis and risk stratification in patients with genetic heart diseases (GHDs).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients coming to Mayo Clinic’s Genetic Heart Rhythm Clinic for evaluation or follow-up for their GHD.
Patients 18 years and older.

Exclusion Criteria:

Patient inability or unwillingness to participate in the study.
Patients 17 years and under.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Michael Ackerman, M.D., Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Michael Ackerman, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials